Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN)

Piercarlo Sarzi-Puttini, M. Antivalle, A. Marchesoni, E. G. Favalli, R. Gorla, M. Filippini, R. Caporali, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages, which consist of joint destruction. Clinical trials have shown that anti-tumour necrosis factor (TNF) drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs). At about the same time as the European approval of the third anti-TNF agent for treating rheumatoid arthritis (RA) patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of patients with RA treated with biological response modifiers. Since 1999, all patients with RA (ACR criteria) and treated with at least one dose of an anti-TNF agent at four Rheumatology Centres in Lombardy (northwest Italy) have been included in the Lombardy Rheumatology Network (LORHEN) registry in order to track the efficacy and safety of the three available TNF inhibitors during the first three years of treatment.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalReumatismo
Volume60
Issue number4
Publication statusPublished - 2008

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Safety
Rheumatology
Antirheumatic Agents
Synovitis
Immunologic Factors
Italy
Autoimmune Diseases
Registries
Joints
Clinical Trials
Databases
Bone and Bones
Pharmaceutical Preparations
Therapeutics

Keywords

  • Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR])
  • Lombardy Rheumatology Network (LORHEN) registry
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Sarzi-Puttini, P., Antivalle, M., Marchesoni, A., Favalli, E. G., Gorla, R., Filippini, M., ... Atzeni, F. (2008). Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo, 60(4), 290-295.

Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). / Sarzi-Puttini, Piercarlo; Antivalle, M.; Marchesoni, A.; Favalli, E. G.; Gorla, R.; Filippini, M.; Caporali, R.; Bobbio-Pallavicini, F.; Montecucco, C.; Atzeni, F.

In: Reumatismo, Vol. 60, No. 4, 2008, p. 290-295.

Research output: Contribution to journalArticle

Sarzi-Puttini, P, Antivalle, M, Marchesoni, A, Favalli, EG, Gorla, R, Filippini, M, Caporali, R, Bobbio-Pallavicini, F, Montecucco, C & Atzeni, F 2008, 'Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN)', Reumatismo, vol. 60, no. 4, pp. 290-295.
Sarzi-Puttini P, Antivalle M, Marchesoni A, Favalli EG, Gorla R, Filippini M et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo. 2008;60(4):290-295.
Sarzi-Puttini, Piercarlo ; Antivalle, M. ; Marchesoni, A. ; Favalli, E. G. ; Gorla, R. ; Filippini, M. ; Caporali, R. ; Bobbio-Pallavicini, F. ; Montecucco, C. ; Atzeni, F. / Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). In: Reumatismo. 2008 ; Vol. 60, No. 4. pp. 290-295.
@article{e7e9eceb9a3f43879982545b6c7d7bb6,
title = "Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN)",
abstract = "Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages, which consist of joint destruction. Clinical trials have shown that anti-tumour necrosis factor (TNF) drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs). At about the same time as the European approval of the third anti-TNF agent for treating rheumatoid arthritis (RA) patients, the Italian Society of Rheumatology (Societ{\`a} Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of patients with RA treated with biological response modifiers. Since 1999, all patients with RA (ACR criteria) and treated with at least one dose of an anti-TNF agent at four Rheumatology Centres in Lombardy (northwest Italy) have been included in the Lombardy Rheumatology Network (LORHEN) registry in order to track the efficacy and safety of the three available TNF inhibitors during the first three years of treatment.",
keywords = "Italian Society of Rheumatology (Societ{\`a} Italiana di Reumatologia [SIR]), Lombardy Rheumatology Network (LORHEN) registry, Rheumatoid arthritis",
author = "Piercarlo Sarzi-Puttini and M. Antivalle and A. Marchesoni and Favalli, {E. G.} and R. Gorla and M. Filippini and R. Caporali and F. Bobbio-Pallavicini and C. Montecucco and F. Atzeni",
year = "2008",
language = "English",
volume = "60",
pages = "290--295",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN)

AU - Sarzi-Puttini, Piercarlo

AU - Antivalle, M.

AU - Marchesoni, A.

AU - Favalli, E. G.

AU - Gorla, R.

AU - Filippini, M.

AU - Caporali, R.

AU - Bobbio-Pallavicini, F.

AU - Montecucco, C.

AU - Atzeni, F.

PY - 2008

Y1 - 2008

N2 - Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages, which consist of joint destruction. Clinical trials have shown that anti-tumour necrosis factor (TNF) drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs). At about the same time as the European approval of the third anti-TNF agent for treating rheumatoid arthritis (RA) patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of patients with RA treated with biological response modifiers. Since 1999, all patients with RA (ACR criteria) and treated with at least one dose of an anti-TNF agent at four Rheumatology Centres in Lombardy (northwest Italy) have been included in the Lombardy Rheumatology Network (LORHEN) registry in order to track the efficacy and safety of the three available TNF inhibitors during the first three years of treatment.

AB - Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages, which consist of joint destruction. Clinical trials have shown that anti-tumour necrosis factor (TNF) drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs). At about the same time as the European approval of the third anti-TNF agent for treating rheumatoid arthritis (RA) patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of patients with RA treated with biological response modifiers. Since 1999, all patients with RA (ACR criteria) and treated with at least one dose of an anti-TNF agent at four Rheumatology Centres in Lombardy (northwest Italy) have been included in the Lombardy Rheumatology Network (LORHEN) registry in order to track the efficacy and safety of the three available TNF inhibitors during the first three years of treatment.

KW - Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR])

KW - Lombardy Rheumatology Network (LORHEN) registry

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=61549086004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549086004&partnerID=8YFLogxK

M3 - Article

C2 - 19132154

AN - SCOPUS:61549086004

VL - 60

SP - 290

EP - 295

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - 4

ER -